サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1713182

豚の自家ワクチンの世界市場：業界分析、規模、シェア、成長、動向、予測（2025年～2032年）

Swine Autogenous Vaccine Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

出版日
ページ情報
英文 150 Pages
納期
2～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
豚の自家ワクチンの世界市場：業界分析、規模、シェア、成長、動向、予測（2025年～2032年）
出版日: 2025年04月23日
発行: Persistence Market Research
ページ情報: 英文 150 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の豚の自家ワクチンの市場規模は、2025年に4,870万米ドルになるとみられ、2025年～2032年の予測期間に5.3%のCAGRで拡大し、2032年には7,000万米ドルに達すると予測されています。

豚の自家ワクチンは、特定の群れから分離された病原体を使用して開発されたカスタムメイドのワクチンです。これらのワクチンは、市販のワクチンでは対処できない可能性のある局所的な疾病株に対する標的免疫を提供します。豚赤痢、Mycoplasma hyopneumoniae、Streptococcus suis、豚繁殖・呼吸器症候群（PRRS）などの細菌やウイルス感染と闘うために、豚群で一般的に使用されています。この市場は、商業用養豚生産者、動物病院、動物衛生企業などを対象としており、疾病の発生率の増加、牛群に特化したソリューションへの需要の高まり、バイオセキュリティと動物の健康管理への関心の高まりが成長の原動力となっています。

世界の豚の自家ワクチン市場は、豚の個体群における感染症の蔓延の増加によって後押しされており、多くの場合、高密度の農業慣行や抗生物質耐性によって悪化しています。これらのワクチンは、地域特有の病原体に対処し、抗生物質の使用を削減する戦略的な手段を養豚業者に提供し、抗菌剤耐性（AMR）と闘う世界の取り組みと一致します。加えて、予防獣医療に対する意識の高まり、食肉用豚の生産量の増加、万能ではない市販ワクチンの不足により、畜産農家は個別化されたワクチン戦略を採用するようになっています。自家ワクチンの製造と使用に対する規制上の支援が、市場の成長をさらに促進しています。

良好な市場環境にもかかわらず、豚の自家ワクチン市場はいくつかの課題に直面しています。自家ワクチン製造に関する規制上の障壁や複雑な承認プロセスは国によって大きく異なるため、国境を越えた適用が制限される可能性があります。自家ワクチンの生産には時間がかかり、高度なバイオセーフティ能力と診断能力が要求されるため、小規模農場にとってはコスト負担が大きくなります。さらに、保存期間が限られており、製造、保管、流通のための標準化されたプロトコルがないため、ワクチンの有効性と拡張性が制限される可能性があります。市場の勢いを維持するためには、インフラ、診断スピード、規制の調和を改善する必要があります。

同市場は、分子診断学と次世代シーケンサー（NGS）技術の統合により、牛群に特異的な病原体の迅速な同定を可能にし、大きな成長機会をもたらします。精密畜産と牛群の健康モニタリングシステムの導入は、自家ワクチンのテーラーメイド適用をサポートし、動物の健康成果と経営効率を高める。新興市場、特にアジア太平洋とラテンアメリカは、豚肉消費の増加と商業養豚生産の拡大により、未開拓の可能性を秘めています。獣医サービスプロバイダー、研究機関、バイオテクノロジー企業間の戦略的パートナーシップは、技術革新を加速し、ワクチン開発を合理化し、市場開拓を強化することができます。

当レポートでは、世界の豚の自家ワクチン市場について調査し、株タイプ別、用途別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場の範囲と定義
  • 市場力学
  • マクロ経済要因
  • COVID-19の影響分析
  • 予測要因- 関連性と影響

第3章 付加価値のある洞察

第4章 世界の豚の自家ワクチン市場の見通し

  • 主なハイライト
  • 市場規模分析と予測
    • 過去の市場規模（100万米ドル）分析、2019年～2024年
    • 現在の市場規模（100万米ドル）分析と予測、2025年～2032年
  • 世界の豚の自家ワクチン市場の見通し：株タイプ別
    • イントロダクション/主な調査結果
    • 過去の市場規模（100万米ドル）分析、株タイプ別、2019年～2024年
    • 現在の市場規模（100万米ドル）分析と予測、株タイプ別、2025年～2032年
      • 細菌株
      • ウイルス株
    • 市場の魅力分析：、株タイプ別
  • 世界の豚の自家ワクチン市場の見通し：用途別
    • イントロダクション/主な調査結果
    • 過去の市場規模（100万米ドル）分析、用途別、2019年～2024年
    • 現在の市場規模（100万米ドル）分析と予測、用途別、2025年～2032年
      • 呼吸器疾患
      • 消化器疾患
      • 生殖疾患
      • 全身感染症
      • その他
    • 市場の魅力分析：用途別
  • 世界の豚の自家ワクチン市場の見通し：エンドユーザー別
    • イントロダクション/主な調査結果
    • 過去の市場規模（100万米ドル）分析、エンドユーザー別、2019年～2024年
    • 現在の市場規模（100万米ドル）分析と予測、エンドユーザー別、2025年～2032年
      • 獣医クリニックと病院
      • 畜産会社
      • 研究・学術機関
    • 市場の魅力分析：エンドユーザー別

第5章 世界の豚の自家ワクチン市場の見通し：地域別

  • 主なハイライト
  • 過去の市場規模（100万米ドル）分析、地域別、2019年～2024年
  • 現在の市場規模（100万米ドル）分析と予測、地域別、2025年～2032年
    • 北米
    • 欧州
    • 東アジア
    • 南アジアとオセアニア
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場の魅力分析：地域別

第6章 北米の豚の自家ワクチン市場の見通し

第7章 欧州の豚の自家ワクチン市場の見通し

第8章 東アジアの豚の自家ワクチン市場の見通し

第9章 南アジアおよびオセアニアの豚の自家ワクチン市場の見通し

第10章 ラテンアメリカの豚の自家ワクチン市場の見通し

第11章 中東・アフリカの豚の自家ワクチン市場の見通し

第12章 競合情勢

  • 市場シェア分析、2025年
  • 市場構造
  • 企業プロファイル（詳細- 概要、財務、戦略、最近の動向）
    • Ceva
    • Phibro Animal Health Corporation
    • SAN Group Biotech Germany GmbH
    • Exopol
    • Vaxxinova
    • American Animal Health, Inc.
    • BIMEDA（R）BIOLOGICALS
    • Dopharma
    • Elanco
    • Treidlia Biovet
    • Cambridge Technologies
    • Addison Biological Laboratory
    • VST Labs
    • INVAC Deutschland GmbH
    • Merck &Co., Inc.
    • Wixbio
    • Boehringer Ingelheim Animal Health USA Inc.
    • Osterreichische Agentur fur Gesundheit und Ernahrungssicherheit GmbH
    • Dyntec
    • Aptimmune
    • その他

第13章 付録

目次
Product Code: PMRREP35209

Persistence Market Research has recently released a comprehensive report on the worldwide market for swine autogenous vaccines. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global swine autogenous vaccines market from 2025 to 2032.

Key Insights:

  • Swine Autogenous Vaccines Market Size (2025E): USD 48.7 Million
  • Projected Market Value (2032F): USD 70.0 Million
  • Global Market Growth Rate (CAGR 2025 to 2032): 5.3%

Swine Autogenous Vaccines Market - Report Scope:

Swine autogenous vaccines are custom-made vaccines developed using pathogens isolated from a specific herd. These vaccines provide targeted immunity against local disease strains that may not be addressed by commercial vaccines. They are commonly used in swine herds to combat bacterial and viral infections such as swine dysentery, Mycoplasma hyopneumoniae, Streptococcus suis, and porcine reproductive and respiratory syndrome (PRRS). The market caters to commercial swine producers, veterinary clinics, and animal health companies, with growth driven by increasing disease incidence, rising demand for herd-specific solutions, and a greater focus on biosecurity and animal health management.

Market Growth Drivers:

The global swine autogenous vaccines market is propelled by the rising prevalence of infectious diseases in swine populations, often exacerbated by high-density farming practices and antibiotic resistance. These vaccines offer swine producers a strategic tool to address region-specific pathogens and reduce antibiotic use, aligning with global efforts to combat antimicrobial resistance (AMR). Additionally, growing awareness of preventive veterinary care, increasing swine production for meat consumption, and the inadequacy of one-size-fits-all commercial vaccines are prompting livestock farmers to adopt personalized vaccination strategies. Regulatory support for autogenous vaccine manufacturing and use is further facilitating market growth.

Market Restraints:

Despite favorable market conditions, the swine autogenous vaccines market faces several challenges. Regulatory barriers and complex approval processes for autogenous vaccine production vary significantly by country, potentially limiting cross-border applications. The production of autogenous vaccines is time-intensive and demands advanced biosafety and diagnostic capabilities, which can be cost-prohibitive for small farms. Moreover, limited shelf life and lack of standardized protocols for production, storage, and distribution can restrict vaccine effectiveness and scalability. These issues necessitate improvements in infrastructure, diagnostic speed, and regulatory harmonization to sustain market momentum.

Market Opportunities:

The market presents substantial growth opportunities through the integration of molecular diagnostics and next-generation sequencing (NGS) technologies, which enable faster identification of herd-specific pathogens. The adoption of precision livestock farming and herd health monitoring systems supports the tailored application of autogenous vaccines, enhancing animal health outcomes and operational efficiency. Emerging markets, particularly in Asia-Pacific and Latin America, offer untapped potential due to increasing pork consumption and expanding commercial swine production. Strategic partnerships between veterinary service providers, research institutions, and biotechnology firms can accelerate innovation, streamline vaccine development, and enhance market access.

Key Questions Answered in the Report:

  • What are the major factors driving the global swine autogenous vaccines market?
  • Which diseases are most commonly targeted using autogenous vaccines in swine?
  • How are advancements in diagnostics and biotechnology influencing vaccine development?
  • Who are the key players in the swine autogenous vaccines market, and what strategies are they employing for growth?
  • What are the regional trends and future opportunities shaping this market?

Competitive Intelligence and Business Strategy:

Leading players in the global swine autogenous vaccines market, including Newport Laboratories (Boehringer Ingelheim), Cambridge Technologies, Elanco Animal Health, and Huvepharma, focus on expanding their custom vaccine development capabilities and enhancing diagnostic support services. These companies are investing in research and development to create faster, safer, and more effective vaccine solutions tailored to farm-level disease profiles. Collaboration with veterinarians and animal health organizations ensures a continuous supply of herd-specific vaccines. Furthermore, companies are exploring digital platforms for vaccination records, herd management, and diagnostics integration to strengthen client engagement and treatment efficacy.

Key Companies Profiled:

  • Ceva
  • Phibro Animal Health Corporation
  • SAN Group Biotech Germany GmbH
  • Exopol
  • Vaxxinova
  • ?American Animal Health, Inc.
  • BIMEDA(R) BIOLOGICALS
  • Dopharma
  • Elanco
  • Treidlia Biovet
  • Cambridge Technologies
  • Addison Biological Laboratory
  • VST Labs
  • INVAC Deutschland GmbH
  • Merck & Co., Inc.
  • Wixbio
  • Boehringer Ingelheim Animal Health USA Inc.
  • Osterreichische Agentur fur Gesundheit und Ernahrungssicherheit GmbH
  • Dyntec
  • Aptimmune

Market Segmentation

By Strain Type

  • Bacterial Strain
  • Viral Strain

By Application

  • Respiratory Diseases
  • Gastrointestinal Diseases
  • Reproductive Diseases
  • Systemic Infections
  • Others

By End-user

  • Veterinary Clinics and Hospitals
  • Livestock Farming Companies
  • Research and Academic Institutes

By Region

  • North America
  • Europe
  • East Asia
  • South Asia and Oceania
  • Latin America
  • Middle East and Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Swine Autogenous Vaccines Market Snapshot, 2025-2032
  • 1.2. Market Opportunity Assessment, 2025-2032, US$ Mn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Challenges
    • 2.2.5. Key Trends
  • 2.3. Macro-Economic Factors
    • 2.3.1. Global Sectorial Outlook
    • 2.3.2. Global GDP Growth Outlook
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Product Adoption Analysis
  • 3.2. Disease Epidemiology
  • 3.3. Technological Advancement
  • 3.4. Regulatory Landscape
  • 3.5. Value Chain Analysis
  • 3.6. Key Deals and Mergers
  • 3.7. PESTLE Analysis
  • 3.8. Porter's Five Force Analysis

4. Global Swine Autogenous Vaccines Market Outlook:

  • 4.1. Key Highlights
    • 4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
    • 4.1.2. Absolute $ Opportunity
  • 4.2. Market Size (US$ Mn) Analysis and Forecast
    • 4.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2024
    • 4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2025-2032
  • 4.3. Global Swine Autogenous Vaccines Market Outlook: Strain Type
    • 4.3.1. Introduction / Key Findings
    • 4.3.2. Historical Market Size (US$ Mn) Analysis, by Strain Type, 2019-2024
    • 4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, by Strain Type, 2025-2032
      • 4.3.3.1. Bacterial Strain
      • 4.3.3.2. Viral Strain
    • 4.3.4. Market Attractiveness Analysis: Strain Type
  • 4.4. Global Swine Autogenous Vaccines Market Outlook: Application
    • 4.4.1. Introduction / Key Findings
    • 4.4.2. Historical Market Size (US$ Mn) Analysis, by Application, 2019-2024
    • 4.4.3. Current Market Size (US$ Mn) Analysis and Forecast, by Application, 2025-2032
      • 4.4.3.1. Respiratory Diseases
      • 4.4.3.2. Gastrointestinal Diseases
      • 4.4.3.3. Reproductive Diseases
      • 4.4.3.4. Systemic Infections
      • 4.4.3.5. Others
    • 4.4.4. Market Attractiveness Analysis: Application
  • 4.5. Global Swine Autogenous Vaccines Market Outlook: End User
    • 4.5.1. Introduction / Key Findings
    • 4.5.2. Historical Market Size (US$ Mn) Analysis, by End User, 2019-2024
    • 4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, by End User, 2025-2032
      • 4.5.3.1. Veterinary Clinics and Hospitals
      • 4.5.3.2. Livestock Farming Companies
      • 4.5.3.3. Research and Academic Institutes
    • 4.5.4. Market Attractiveness Analysis: End User

5. Global Swine Autogenous Vaccines Market Outlook: Region

  • 5.1. Key Highlights
  • 5.2. Historical Market Size (US$ Mn) Analysis, by Region, 2019-2024
  • 5.3. Current Market Size (US$ Mn) Analysis and Forecast by Region, 2025-2032
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. East Asia
    • 5.3.4. South Asia and Oceania
    • 5.3.5. Latin America
    • 5.3.6. Middle East & Africa
  • 5.4. Market Attractiveness Analysis: Region

6. North America Swine Autogenous Vaccines Market Outlook:

  • 6.1. Key Highlights
  • 6.2. Historical Market Size (US$ Mn) Analysis, by Market, 2019-2024
    • 6.2.1. by Country
    • 6.2.2. by Strain Type
    • 6.2.3. by Application
    • 6.2.4. by End User
  • 6.3. Current Market Size (US$ Mn) Analysis and Forecast by Country, 2025-2032
    • 6.3.1. U.S.
    • 6.3.2. Canada
  • 6.4. Current Market Size (US$ Mn) Analysis and Forecast by Strain Type, 2025-2032
    • 6.4.1. Bacterial Strain
    • 6.4.2. Viral Strain
  • 6.5. Current Market Size (US$ Mn) Analysis and Forecast by Application, 2025-2032
    • 6.5.1. Respiratory Diseases
    • 6.5.2. Gastrointestinal Diseases
    • 6.5.3. Reproductive Diseases
    • 6.5.4. Systemic Infections
    • 6.5.5. Others
  • 6.6. Current Market Size (US$ Mn) Analysis and Forecast by End User, 2025-2032
    • 6.6.1. Veterinary Clinics and Hospitals
    • 6.6.2. Livestock Farming Companies
    • 6.6.3. Research and Academic Institutes
  • 6.7. Market Attractiveness Analysis

7. Europe Swine Autogenous Vaccines Market Outlook:

  • 7.1. Key Highlights
  • 7.2. Historical Market Size (US$ Mn) Analysis, by Market, 2019-2024
    • 7.2.1. by Country
    • 7.2.2. by Strain Type
    • 7.2.3. by Application
    • 7.2.4. by End User
  • 7.3. Current Market Size (US$ Mn) Analysis and Forecast, by Country, 2025-2032
    • 7.3.1. Germany
    • 7.3.2. France
    • 7.3.3. U.K.
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Russia
    • 7.3.7. Turkey
    • 7.3.8. Rest of Europe
  • 7.4. Current Market Size (US$ Mn) Analysis and Forecast, by Strain Type, 2025-2032
    • 7.4.1. Bacterial Strain
    • 7.4.2. Viral Strain
  • 7.5. Current Market Size (US$ Mn) Analysis and Forecast, by Application, 2025-2032
    • 7.5.1. Respiratory Diseases
    • 7.5.2. Gastrointestinal Diseases
    • 7.5.3. Reproductive Diseases
    • 7.5.4. Systemic Infections
    • 7.5.5. Others
  • 7.6. Current Market Size (US$ Mn) Analysis and Forecast, by End User, 2025-2032
    • 7.6.1. Veterinary Clinics and Hospitals
    • 7.6.2. Livestock Farming Companies
    • 7.6.3. Research and Academic Institutes
  • 7.7. Market Attractiveness Analysis

8. East Asia Swine Autogenous Vaccines Market Outlook:

  • 8.1. Key Highlights
  • 8.2. Historical Market Size (US$ Mn) Analysis, by Market, 2019-2024
    • 8.2.1. by Country
    • 8.2.2. by Strain Type
    • 8.2.3. by Application
    • 8.2.4. by End User
  • 8.3. Current Market Size (US$ Mn) Analysis and Forecast, by Country, 2025-2032
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. South Korea
  • 8.4. Current Market Size (US$ Mn) Analysis and Forecast, by Strain Type, 2025-2032
    • 8.4.1. Bacterial Strain
    • 8.4.2. Viral Strain
  • 8.5. Current Market Size (US$ Mn) Analysis and Forecast, by Application, 2025-2032
    • 8.5.1. Respiratory Diseases
    • 8.5.2. Gastrointestinal Diseases
    • 8.5.3. Reproductive Diseases
    • 8.5.4. Systemic Infections
    • 8.5.5. Others
  • 8.6. Current Market Size (US$ Mn) Analysis and Forecast, by End User, 2025-2032
    • 8.6.1. Veterinary Clinics and Hospitals
    • 8.6.2. Livestock Farming Companies
    • 8.6.3. Research and Academic Institutes
  • 8.7. Market Attractiveness Analysis

9. South Asia & Oceania Swine Autogenous Vaccines Market Outlook:

  • 9.1. Key Highlights
  • 9.2. Historical Market Size (US$ Mn) Analysis, by Market, 2019-2024
    • 9.2.1. by Country
    • 9.2.2. by Strain Type
    • 9.2.3. by Application
    • 9.2.4. by End User
  • 9.3. Current Market Size (US$ Mn) Analysis and Forecast, by Country, 2025-2032
    • 9.3.1. India
    • 9.3.2. Southeast Asia
    • 9.3.3. ANZ
    • 9.3.4. Rest of South Asia & Oceania
  • 9.4. Current Market Size (US$ Mn) Analysis and Forecast, by Strain Type, 2025-2032
    • 9.4.1. Bacterial Strain
    • 9.4.2. Viral Strain
  • 9.5. Current Market Size (US$ Mn) Analysis and Forecast, by Application, 2025-2032
    • 9.5.1. Respiratory Diseases
    • 9.5.2. Gastrointestinal Diseases
    • 9.5.3. Reproductive Diseases
    • 9.5.4. Systemic Infections
    • 9.5.5. Others
  • 9.6. Current Market Size (US$ Mn) Analysis and Forecast, by End User, 2025-2032
    • 9.6.1. Veterinary Clinics and Hospitals
    • 9.6.2. Livestock Farming Companies
    • 9.6.3. Research and Academic Institutes
  • 9.7. Market Attractiveness Analysis

10. Latin America Swine Autogenous Vaccines Market Outlook:

  • 10.1. Key Highlights
  • 10.2. Historical Market Size (US$ Mn) Analysis, by Market, 2019-2024
    • 10.2.1. by Country
    • 10.2.2. by Strain Type
    • 10.2.3. by Application
    • 10.2.4. by End User
  • 10.3. Current Market Size (US$ Mn) Analysis and Forecast, by Country, 2025-2032
    • 10.3.1. Brazil
    • 10.3.2. Mexico
    • 10.3.3. Rest of Latin America
  • 10.4. Current Market Size (US$ Mn) Analysis and Forecast, by Strain Type, 2025-2032
    • 10.4.1. Bacterial Strain
    • 10.4.2. Viral Strain
  • 10.5. Current Market Size (US$ Mn) Analysis and Forecast, by Application, 2025-2032
    • 10.5.1. Respiratory Diseases
    • 10.5.2. Gastrointestinal Diseases
    • 10.5.3. Reproductive Diseases
    • 10.5.4. Systemic Infections
    • 10.5.5. Others
  • 10.6. Current Market Size (US$ Mn) Analysis and Forecast, by End User, 2025-2032
    • 10.6.1. Veterinary Clinics and Hospitals
    • 10.6.2. Livestock Farming Companies
    • 10.6.3. Research and Academic Institutes
  • 10.7. Market Attractiveness Analysis

11. Middle East & Africa Swine Autogenous Vaccines Market Outlook:

  • 11.1. Key Highlights
  • 11.2. Historical Market Size (US$ Mn) Analysis, by Market, 2019-2024
    • 11.2.1. by Country
    • 11.2.2. by Strain Type
    • 11.2.3. by Application
    • 11.2.4. by End User
  • 11.3. Current Market Size (US$ Mn) Analysis and Forecast, by Country, 2025-2032
    • 11.3.1. GCC Countries
    • 11.3.2. Egypt
    • 11.3.3. South Africa
    • 11.3.4. Northern Africa
    • 11.3.5. Rest of Middle East & Africa
  • 11.4. Current Market Size (US$ Mn) Analysis and Forecast, by Strain Type, 2025-2032
    • 11.4.1. Bacterial Strain
    • 11.4.2. Viral Strain
  • 11.5. Current Market Size (US$ Mn) Analysis and Forecast, by Application, 2025-2032
    • 11.5.1. Respiratory Diseases
    • 11.5.2. Gastrointestinal Diseases
    • 11.5.3. Reproductive Diseases
    • 11.5.4. Systemic Infections
    • 11.5.5. Others
  • 11.6. Current Market Size (US$ Mn) Analysis and Forecast, by End User, 2025-2032
    • 11.6.1. Veterinary Clinics and Hospitals
    • 11.6.2. Livestock Farming Companies
    • 11.6.3. Research and Academic Institutes
  • 11.7. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Share Analysis, 2025
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping by Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. Ceva
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Products
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. Phibro Animal Health Corporation
    • 12.3.3. SAN Group Biotech Germany GmbH
    • 12.3.4. Exopol
    • 12.3.5. Vaxxinova
    • 12.3.6. ?American Animal Health, Inc.
    • 12.3.7. BIMEDA(R) BIOLOGICALS
    • 12.3.8. Dopharma
    • 12.3.9. Elanco
    • 12.3.10. Treidlia Biovet
    • 12.3.11. Cambridge Technologies
    • 12.3.12. Addison Biological Laboratory
    • 12.3.13. VST Labs
    • 12.3.14. INVAC Deutschland GmbH
    • 12.3.15. Merck & Co., Inc.
    • 12.3.16. Wixbio
    • 12.3.17. Boehringer Ingelheim Animal Health USA Inc.
    • 12.3.18. Osterreichische Agentur fur Gesundheit und Ernahrungssicherheit GmbH
    • 12.3.19. Dyntec
    • 12.3.20. Aptimmune
    • 12.3.21. Others

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations